Multiple endocrine neoplasia type 2 cost-effectiveness of therapy: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Cost- | Cost-effective therapy of multiple endocrine neoplasia type 2 include targeted therapy, prophylactic [[thyroidectomy]] and restricted molecular screening. | ||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
===Methods for cost effectiveness of the therapy=== | ===Methods for cost effectiveness of the therapy=== | ||
Revision as of 15:23, 30 September 2015
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
|
FDA on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
|
CDC on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
|
Multiple endocrine neoplasia type 2 cost-effectiveness of therapy in the news |
|
Blogs on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Cost-effective therapy of multiple endocrine neoplasia type 2 include targeted therapy, prophylactic thyroidectomy and restricted molecular screening.
Cost-Effectiveness of Therapy
Methods for cost effectiveness of the therapy
- Molecular screening of RET gene limiting to exon 10,11 and 16 is an effective way of reducing the cost of management of thyroidectomy.
- For diagnosis of multiple endocrine neoplasia type 2B, investigation of exon 16 is adequate and this further is a cost effective method.[1]
- Prophylactic thyroidectomy of patients screened positive for RET gene is a cost effective way of management of thyroidectomy.[2]
- Targeted therapy of multiple endocrine neoplasia type 2B yields lower costs that the present management of multiple endocrine neoplasia type 2.
References
- ↑ Chang CF, Yang WS, Su YN, Wu IL, Chang TC (2009). "Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan". J Formos Med Assoc. 108 (5): 402–8. doi:10.1016/S0929-6646(09)60084-X. PMID 19443294.
- ↑ Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC; et al. (2002). "Gastrointestinal manifestations of multiple endocrine neoplasia type 2". Ann Surg. 235 (5): 648–54, discussion 654-5. PMC 1422490. PMID 11981210.